The U.S. Department of Justice under the Trump administration formally initiated the process to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act on July 17, 2026. The policy shift, first reported by finance.yahoo.com, ignited an immediate rally across U.S. and Canadian cannabis equities, with multistate operators (MSOs) like Green Thumb Industries and Curaleaf Holdings surging over 20%. The move directly addresses a primary financial constraint for U.S. operators by paving the way for tax code 280E repeal, which could instantly improve net profitability by 20-30% for companies with significant U.S. exposure, including Tilray Brands and Canopy Growth Corporation.
Context — [why this matters now]
The cannabis sector has traded primarily on regulatory speculation since Canada's federal legalization in October 2018. The current macro backdrop of moderating inflation and stable interest rates has increased investor appetite for growth-sensitive, policy-driven equities. The catalyst for this specific action stems from a revived and accelerated process based on a 2024 Department of Health and Human Services review, which recommended rescheduling. The Trump administration prioritized this action as a states' rights and economic liberty issue, differing from the Biden administration's more gradual approach of pardons and executive studies. The last comparable regulatory surge occurred in late 2020 and early 2021, when anticipation of federal reform following the Georgia Senate runoffs propelled the AdvisorShares Pure US Cannabis ETF (MSOS) to gains exceeding 150% in three months.
Data — [what the numbers show]
The market response on July 17 was immediate and substantial. The Horizons US Marijuana Index ETF (HMUS) gained 18.7% on volume 480% above its 30-day average. Green Thumb Industries (GTBIF) closed at $12.45, up 22.3% for the session. Curaleaf Holdings (CURLF) advanced 20.1% to $5.72. Canadian producer Tilray Brands (TLRY), which derives an estimated 40% of its revenue from U.S. cannabis operations, rose 18.5%. Canopy Growth Corporation (CGC), which holds options to acquire U.S. MSOs upon federal permissibility, surged 31.8%. This outperformed the Nasdaq Composite, which was flat on the day. The combined market capitalization of the five largest U.S. MSOs increased by approximately $4.2 billion in a single session.
| Ticker | Price Change | Volume vs. Average |
|---|
| GTBIF | +22.3% | 350% |
| CURLF | +20.1% | 410% |
| TLRY | +18.5% | 290% |
| CGC | +31.8% | 620% |
Analysis — [what it means for markets / sectors]
The most direct second-order effect is a dramatic improvement in the fundamental outlook for U.S. plant-touching operators. Rescheduling enables the potential repeal of IRS code 280E, which currently prohibits cannabis companies from deducting standard business expenses, effectively imposing marginal tax rates of 70% or higher. Its removal could boost Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for profitable MSOs by 25-50%. A key counter-argument is that rescheduling alone does not equate to full federal legalization, leaving interstate commerce and banking access unresolved. Institutional flow data indicates rapid covering of short positions that had built up in ETFs like MSOS throughout Q2 2026, while long-only funds initiated new positions in the largest MSOs by market cap.
Outlook — [what to watch next]
The next immediate catalyst is the public comment period overseen by the Justice Department, which will last for 60 days. Following that, a final rule must be published in the Federal Register, a process expected to conclude by the end of Q1 2027. Traders are monitoring key technical resistance levels for GTBIF at $14.50, a zone that has contained rallies since early 2025. The status of the SAFER Banking Act in the Senate remains a critical variable, as its passage would compound the positive effects of rescheduling by granting full banking access. Congressional hearings on the scheduling change are likely to be scheduled for September 2026.
Frequently Asked Questions
What does marijuana rescheduling mean for retail investors?
Rescheduling makes legitimate cannabis companies significantly more investable by reducing regulatory risk and improving profitability. For retail investors, this opens access to a sector previously burdened by existential legal threats and punitive taxation. Exchange-listed ETFs like MSOS and HMUS provide direct exposure, though volatility remains high. It does not change the fact that direct plant-touching businesses remain illegal under federal law, creating a persistent legal dichotomy.
How does Schedule III compare to full legalization?
Schedule III classification acknowledges accepted medical use and a lower potential for abuse but is not legalization. Cannabis would remain a controlled substance, its cultivation and distribution would still be federally regulated, and state-by-state legality would persist. This differs from full legalization, which would deschedule cannabis entirely, treat it like alcohol, and likely permit interstate commerce. The economic impact of rescheduling is primarily financial (taxes), while legalization is operational (logistics, expansion).
Which ancillary sectors benefit from cannabis rescheduling?
Rescheduling provides a tailwind for ancillary sectors including cannabis-focused real estate investment trusts (REITs) like Innovative Industrial Properties, hydroponics and farming technology suppliers, and financial technology companies enabling payment processing. Pharmaceutical companies with research programs into cannabinoid-based drugs also benefit from reduced regulatory hurdles for clinical trials. These sectors gain from increased industry stability and growth without direct exposure to plant-touching regulatory risk.
Bottom Line
Rescheduling is a fundamental, profit-enhancing catalyst that removes the sector's largest financial burden.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
